Nakayama, C., Fang, Q., Daigaku, Y., Aoi, Y., Ito, S., Takahashi, M., Shimatani, R., Minamisawa, T., Ozturk, Y., Kimura, H., Shilatifard, A., Tellier, M. and Nojima, T.

NELF prevents transcriptional readthrough into DNA replication zones in cancer cells.
EMBO Rep., in press (2026)

Tanaka, Y., Sakahara, M., Yamanaka, H., Natsume, Y., Kusama, D., Kumegawa, K., Yoshikawa, H., Abe, Y., Okabayashi, K., Matui, S., Kitagawa, Y., Koshikawa, N., Osumi, H., Shinozaki, E., Nagayama, S., Adachi, J., Maruyama, R. and Yao, R.

Ribosome biogenesis as a potential therapeutic target in KRAS mutant colorectal cancer.
Nat. Commun., 17, 1224 (2026)

Thanongsak, W., Kawahara, M., Nakamoto, M., Homma, K., Sereemaspun, A., Tachaboonyakiat, W., Ruktanonchai, U., Yoshimoto, K., Katayama, R., Matsusaki, M. and Chirachanchai, S.

Concerted pH-responsive performance of chitosan-deoxycholic acid as a polymeric molecular block for cancer cell disruption.
ChemMedChem, 21, e202500587 (2026)

Izumi, H., Sakamoto, T., Uchibori, K., Nishino, K., Sakakibara-Konishi, J., Katayama, R., Nomura, S., Matsumoto, S., Udagawa, H., Shibata, Y., Sakai, T., Nosaki, K., Zenke, Y., Yoh, K., Niho, S. and Goto, K.

Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation.
Cancer Treat. Res. Commun., 46, 101105 (2026)

Wakita, M., Ito, K., Fujii, K., Sakamoto, D., Mikawa, T., Sugawara, S., Zhou, X., Park, J. H., Miyagawa, H., Motooka, D., Ogasawara, E., Ishihara, N., Takahashi, A., Kondoh, H. and Hara, E.

Comparative analysis of senolytic drugs reveals mitochondrial determinants of efficacy and resistance.
Nature aging, in press (2026)

more